Association between pleurodesis before immunotherapy and pneumonitis in non-small cell lung cancer
- 25 September 2025
- journal article
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1194-1200
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort StudyClinical Lung Cancer, 2023
- Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort studyCancer Immunology, Immunotherapy, 2022
- Lung Cancer Survival in Patients With Autoimmune DiseaseJAMA Network Open, 2020
- Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational StudyAdvances in Therapy, 2020
- Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk FactorsJournal of Thoracic Oncology, 2018
- Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesisRespiratory Investigation, 2018
- Bias from outcome misclassification in immunization schedule safety researchPharmacoepidemiology and Drug Safety, 2018
- Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung CancerChest, 2017
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994